Denali Therapeutics (DNLI) Change in Acquisitions & Divestments (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Change in Acquisitions & Divestments data on file, last reported at $220.0 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 36.01% year-over-year to $220.0 million in Q1 2026; TTM through Mar 2026 was $764.3 million, a 18.32% decrease from a year earlier, with the FY2025 full-year figure at $706.0 million, down 38.98% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $220.0 million, down from $275.0 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for DNLI reached as high as $601.1 million in Q3 2023 and fell as low as $107.1 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $303.0 million across 5 years, with a median of $250.5 million in 2022.
• Across the five-year window, Change in Acquisitions & Divestments surged 316.46% in 2023 and sank 67.06% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $364.0 million in 2022, then surged by 34.34% to $489.0 million in 2023, then decreased by 28.22% to $351.0 million in 2024, then decreased by 21.65% to $275.0 million in 2025, then declined by 20.0% to $220.0 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $220.0 million in Q1 2026, $275.0 million in Q4 2025, and $107.1 million in Q3 2025.